BMS Bets On Amira's IPF Drug In $325M Acquisition

The deal expands BMS's inflammatory disease holdings while bringing double-digit returns to the six-year-old startup's earliest investors.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet